<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651675</url>
  </required_header>
  <id_info>
    <org_study_id>823176</org_study_id>
    <nct_id>NCT02651675</nct_id>
  </id_info>
  <brief_title>A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)</brief_title>
  <official_title>A Phase 1/2a, Single Ascending IV Dose Clinical Trial Investigating Human Low Density Lipoprotein Receptor (LDLR) Gene Therapy in Subjects With Homozygous Familial Hypercholesterolemia (HoFH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic metabolic disorder
      characterized by absent or severely reduced capacity to catabolize circulating LDL particles
      by the hepatic LDL receptor. As a consequence, HoFH subjects present abnormal total plasma
      cholesterol (LDL-C) levels, resulting in severe atherosclerosis often leading to early onset
      of cardiovascular disease. Early initiation of aggressive treatment for these patients is
      therefore essential. Unfortunately, despite existing therapies, treated LDL-C levels could
      remain well above acceptable levels. Thus, the functional replacement of the defective LDLR
      via AAV-based liver-directed gene therapy may be a viable approach to treat this disease and
      improve response to current lipid-lowering treatments. This first-in-humans study is intended
      to evaluate the safety of this gene therapy investigational product and assess preliminary
      evidence of efficacy using plasma LDL-C levels as a surrogate biomarker for human LDLR
      transgene expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be asked to participate in an optional kinetics study. Subjects who agree will
      be admitted to the research inpatient unit at University of Pennsylvania or selected sites
      for the LDL kinetics study prior to vector administration.

      The LDL kinetic assessment will be performed using a primed constant infusion of deuterated
      leucine for 12 hours with repeated blood draws up to 48 hours. 2- 14 days following the start
      of the leucine infusion, subjects will be admitted to the research inpatient unit at
      University of Pennsylvania where the AAV8.TBG.hLDLR gene therapy vector will be administered.
      Vital signs will be monitored frequently for 24 hours. Blood will be drawn for safety testing
      daily for 3 days up to 72 hours and then weekly up to 12 weeks. More comprehensive assessment
      of safety parameters will occur every 4 weeks up to 12 weeks. Twelve weeks after vector
      administration, subjects that participated in the first optional kinetics study will be
      re-admitted to the inpatient unit at University of Pennsylvania or selected sites for a
      repeat LDL kinetics study. After this visit subjects will be permitted to resume LDL
      apheresis and/or plasma exchange, and other lipid lowering treatments at the discretion of
      their caring physician. Subjects will have a safety visit with blood draw every 12 weeks up
      to 52 weeks, and will be followed with bi-annual telephone calls and annual lipid tests
      thereafter up to 260 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing investigational product-related adverse events</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Physical examinations; Clinical laboratory parameters; and adverse event reporting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C compared to baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lipid parameters compared to baseline values</measure>
    <time_frame>12 weeks</time_frame>
    <description>total cholesterol (TC); non-high density lipoprotein cholesterol (non-HDL-C); HDL-C; fasting triglycerides (TG); overflow density lipoprotein cholesterol (VLDL-C); lipoprotein(a) (Lp(a)); apolipoprotein B (apoB) and apolipoprotein A-I (apo A-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional catabolic rate (FCR) of LDL apoB</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of investigational product-related adverse events</measure>
    <time_frame>260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lipid parameters compared to baseline values</measure>
    <time_frame>260 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AAV directed hLDLR gene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV directed hLDLR gene therapy</intervention_name>
    <description>A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene</description>
    <arm_group_label>AAV directed hLDLR gene therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be eligible to participate in this study, a subject must meet all of the
        following criteria:

          1. Male or female ≥ 18 years of age.

          2. Untreated and/or treated LDL-C levels and clinical presentation consistent with the
             diagnosis of homozygous FH

          3. Molecularly defined LDLR mutations at both LDLR alleles.

          4. Concurrent allowed lipid lowering medication must be stable for ≥ 4 weeks before the
             baseline visit and must remain stable until 12 weeks after vector administration.
             These include but are not limited to: statins, ezetimibe, bile acid sequestrants,
             PCSK9 inhibitors, and LDL and/or plasma apheresis. Subjects on other lipid-lowering
             medications are eligible for the study but must wash out of these medications for the
             pre-specified time period.

          5. Females of childbearing potential must have a negative pregnancy test at screening and
             baseline visits and be willing to have additional pregnancy tests during the study.

          6. Sexually active subjects (both female and male) must be willing to use a medically
             accepted method of contraception from screening visit until 6 months after vector
             administration

          7. A baseline serum AAV8 NAb titer ≤ 1:10.

          8. Subjects must be able to comprehend and be willing to provide a signed institutional
             review board/ethics committee (IRB/EC) approved Informed Consent Form.

          9. Subjects must be willing to comply with all study-related procedures and be available
             for the duration of the study.

        Exclusion Criteria

        Subjects who meet any of the following exclusion criteria will not be eligible to
        participate in the study:

          1. Unwilling to wash out of the following lipid lowering therapies for the pre-specified
             time period:

               1. niacin &gt; 250 mg/day: within 4 weeks of baseline

               2. fibrates: within 4 weeks of baseline

               3. Lomitapide: within 6 weeks of baseline

               4. Mipomersen: within 24 weeks of baseline

          2. Heart failure defined by the NYHA classification as functional Class III with history
             of hospitalization(s) within 12 weeks of the baseline visit or functional Class IV.

          3. History within 12 weeks of the baseline visit of a myocardial infarction (MI),
             unstable angina leading to hospitalization, coronary artery bypass graft surgery
             (CABG), percutaneous coronary intervention (PCI), uncontrolled cardiac arrhythmia,
             carotid surgery or stenting, stroke, transient ischemic attack, carotid
             revascularization, endovascular procedure or surgical intervention.

          4. Uncontrolled hypertension defined as: systolic blood pressure &gt; 180 mmHg, diastolic
             blood pressure &gt; 95 mmHg.

          5. History of cirrhosis or chronic liver disease based on documented histological
             evaluation or non-invasive imaging or testing.

          6. Documented diagnosis of any of the following liver diseases:

               1. Nonalcoholic steatohepatitis (biopsy-proven)

               2. Alcoholic liver disease

               3. Autoimmune hepatitis

               4. Liver cancer

               5. Primary biliary cirrhosis

               6. Primary sclerosing cholangitis

               7. Wilson's disease

               8. Hemochromatosis

               9. α1 anti-trypsin deficiency

          7. Abnormal LFTs at screening (AST or ALT &gt;2x upper limit of normal (ULN) and/or Total
             Bilirubin of &gt;1.5x ULN unless patient has unconjugated hyperbilirubinemia due to
             Gilbert's syndrome).

          8. Hepatitis B as defined by positive for HepB SAg, or Hep B Core Ab, and/or viral DNA

          9. Chronic active Hepatitis C as defined by positive for HCV Ab and viral RNA.

         10. History of alcohol abuse within 52 weeks.

         11. Certain prohibited medications known to be potentially hepatotoxic, especially those
             that can induce microvesicular or macrovesicular steatosis. These include but are not
             limited to: acutane, amiodarone, HAART medications, heavy acetaminophen use (2g/day
             more than 3 times a week), isoniazid, methotrexate, tetracyclines, tamoxifen,
             valproate.

         12. Current use of systemic corticosteroids or active tuberculosis, systemic fungal
             disease, or other chronic infection.

         13. History of immunodeficiency diseases, including a positive HIV test result.

         14. Chronic renal insufficiency defined as estimated GFR &lt; 30 mL/min.

         15. History of cancer within the past 5 years, except for adequately treated basal cell
             skin cancer, squamous cell skin cancer, or in situ cervical cancer.

         16. Previous organ transplantation.

         17. Administration of an investigational drug within 12 weeks or 5 half-lives of the drug
             (whichever is longer) prior to the screening visit and until 52 weeks after receiving
             AAV8.TBG.hLDLR.

         18. Any major surgical procedure occurring less than 3 months prior to the screening
             visit, or any planned future surgical procedure within 3 months of baseline.

         19. Serious or unstable medical or psychological conditions that, in the opinion of the
             investigator, would compromise the subject's safety or successful participation in the
             study.

         20. A baseline serum AAV8 NAb titer &gt; 1:10.

         21. Any other medical condition or finding that would make it not in the subject's best
             interest to participate in the study

         22. Study staff member or any direct family member.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Associate Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <phone>215-746-2834</phone>
    <email>mcuchel@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Baum, MD</last_name>
      <phone>561-756-8206</phone>
      <email>sjbaum@fpim.org</email>
    </contact>
    <investigator>
      <last_name>Seth Baum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Moriarty, MD</last_name>
      <phone>913-588-4064</phone>
      <email>pmoriart@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie-Ann Dutton</last_name>
      <phone>913-588-4064</phone>
      <email>jdutton@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul B Duell, MD</last_name>
      <phone>503-494-2007</phone>
      <email>duellb@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Rose</last_name>
      <phone>503-494-2007</phone>
      <email>rosejil@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Cuchel, MD, PhD</last_name>
      <phone>215-746-2834</phone>
      <email>mcuchel@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Baer, MB, MBA</last_name>
      <phone>215-746-3423</phone>
      <email>baer2@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macrae Fort Linton, MD</last_name>
      <phone>615-936-1450</phone>
    </contact>
    <investigator>
      <last_name>Macrae Fort Linton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gaudet, MD, PhD</last_name>
      <phone>+1 418-541-1077</phone>
      <email>daniel.gaudet@umontreal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Claude Tardif, MD</last_name>
      <phone>+1 514-376-3330</phone>
      <email>jean-claude.tardif@icm-mhi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOUP Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Averna, MD</last_name>
      <phone>+39 328 0212157</phone>
      <email>maurizio.averna@unipa.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonina Giammanco</last_name>
      <phone>+39 3384453633</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Stefanutti, MD, PhD</last_name>
      <phone>+39 06 49970578</phone>
      <email>claudia.stefanutti@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Serafina Di Giacomo</last_name>
      <phone>+39 06 49976521</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine E Roeters van Lennep, MD</last_name>
      <phone>+31 6 52313132</phone>
      <email>j.roetersvanlennep@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Els van der Graaf</last_name>
      <phone>+31(0)10 703 23 24</phone>
      <email>p.vandergraaf@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.baxalta.com/newsroom/press-releases/clinical-trial-bax335.page</url>
    <description>Baxalta, Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B.</description>
  </link>
  <link>
    <url>http://www.news-medical.net</url>
    <description>Biopharma, B., Fifth patient dosed on Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection. 2015</description>
  </link>
  <reference>
    <citation>Goldstein, J.L., H.H. Hobbs, and M.S. Brown, Familial hypercholesterolemia, in the Metabolic and Molecular Bases of Inherited Disease, C.R. Scriver, et al., Editors. 2001, McGraw-Hill Information Services Company: New York. p. 2863-2913.</citation>
  </reference>
  <reference>
    <citation>Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.</citation>
    <PMID>23956253</PMID>
  </reference>
  <reference>
    <citation>Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh GK. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015 Mar 1;36(9):560-5. doi: 10.1093/eurheartj/ehu058. Epub 2014 Feb 28.</citation>
    <PMID>24585268</PMID>
  </reference>
  <reference>
    <citation>Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008 Dec 1;102(11):1438-43. doi: 10.1016/j.amjcard.2008.07.035. Epub 2008 Sep 11.</citation>
    <PMID>19026292</PMID>
  </reference>
  <reference>
    <citation>Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.</citation>
    <PMID>25053660</PMID>
  </reference>
  <reference>
    <citation>Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun;150(2):421-8.</citation>
    <PMID>10856535</PMID>
  </reference>
  <reference>
    <citation>Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar;197(1):400-6. Epub 2007 Aug 28.</citation>
    <PMID>17727860</PMID>
  </reference>
  <reference>
    <citation>Gagné C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 May 28;105(21):2469-75.</citation>
    <PMID>12034651</PMID>
  </reference>
  <reference>
    <citation>Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15;124(20):2202-7. doi: 10.1161/CIRCULATIONAHA.111.042523. Epub 2011 Oct 10.</citation>
    <PMID>21986285</PMID>
  </reference>
  <reference>
    <citation>Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. Arteriosclerosis. 1989 Jan-Feb;9(1 Suppl):I158-63.</citation>
    <PMID>2643427</PMID>
  </reference>
  <reference>
    <citation>Forman MB, Baker SG, Mieny CJ, Joffe BI, Sandler MP, Mendelsohn DU, Seftel HC. Treatment of homozygous familial hypercholesterolaemia with portacaval shunt. Atherosclerosis. 1982 Feb;41(2-3):349-61.</citation>
    <PMID>7066082</PMID>
  </reference>
  <reference>
    <citation>Deckelbaum RJ, Lees RS, Small DM, Hedberg SE, Grundy SM. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia. N Engl J Med. 1977 Mar 3;296(9):465-70.</citation>
    <PMID>834224</PMID>
  </reference>
  <reference>
    <citation>Ibrahim M, El-Hamamsy I, Barbir M, Yacoub MH. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J Cardiovasc Transl Res. 2012 Jun;5(3):351-8. doi: 10.1007/s12265-011-9311-1. Epub 2011 Sep 1.</citation>
    <PMID>21882079</PMID>
  </reference>
  <reference>
    <citation>Küçükkartallar T, Yankol Y, Kanmaz T, Topaloğlu S, Acarli K, Kalayoglu M. Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia. Pediatr Transplant. 2011 May;15(3):281-4. doi: 10.1111/j.1399-3046.2010.01469.x. Epub 2011 Jan 17.</citation>
    <PMID>21235710</PMID>
  </reference>
  <reference>
    <citation>Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW Jr, Hardesty RL, Griffith BP, Iwatsuki S, Zitelli BJ, Gartner JC Jr, Malatack JJ, et al. Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet. 1984 Jun 23;1(8391):1382-3.</citation>
    <PMID>6145836</PMID>
  </reference>
  <reference>
    <citation>Malatack JJ. Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late. Pediatr Transplant. 2011 Mar;15(2):123-5. doi: 10.1111/j.1399-3046.2010.01458.x. Epub 2011 Jan 10.</citation>
    <PMID>21219559</PMID>
  </reference>
  <reference>
    <citation>Thompson GR. LDL apheresis. Atherosclerosis. 2003 Mar;167(1):1-13. Review.</citation>
    <PMID>12618263</PMID>
  </reference>
  <reference>
    <citation>Vella A, Pineda AA, O'Brien T. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc. 2001 Oct;76(10):1039-46. Review.</citation>
    <PMID>11605688</PMID>
  </reference>
  <reference>
    <citation>Eder, A.F. and D.J. Rader, LDL-apheresis for severe refractory dyslipidemia. Today's Therapeutic Trends, 1996. 14: p. 165-179.</citation>
  </reference>
  <reference>
    <citation>Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995 Apr 1;345(8953):811-6.</citation>
    <PMID>7898227</PMID>
  </reference>
  <reference>
    <citation>Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X.</citation>
    <PMID>20227758</PMID>
  </reference>
  <reference>
    <citation>Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148-56.</citation>
    <PMID>17215532</PMID>
  </reference>
  <reference>
    <citation>Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013 Jan 5;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0. Epub 2012 Nov 2.</citation>
    <PMID>23122768</PMID>
  </reference>
  <reference>
    <citation>Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.</citation>
    <PMID>23129602</PMID>
  </reference>
  <reference>
    <citation>Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. doi: 10.1016/S0140-6736(12)60771-5. Epub 2012 May 26.</citation>
    <PMID>22633824</PMID>
  </reference>
  <reference>
    <citation>Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):341-50. doi: 10.1016/S0140-6736(14)61374-X. Epub 2014 Oct 1.</citation>
    <PMID>25282520</PMID>
  </reference>
  <reference>
    <citation>Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6.</citation>
    <PMID>24014831</PMID>
  </reference>
  <reference>
    <citation>Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993 Aug;92(2):883-93.</citation>
    <PMID>8349823</PMID>
  </reference>
  <reference>
    <citation>Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem. 1994 May 6;269(18):13695-702.</citation>
    <PMID>8175805</PMID>
  </reference>
  <reference>
    <citation>Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther. 2004 Oct;11(20):1540-8.</citation>
    <PMID>15269711</PMID>
  </reference>
  <reference>
    <citation>Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med. 2004 Jun;6(6):663-72.</citation>
    <PMID>15170737</PMID>
  </reference>
  <reference>
    <citation>Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd, Stein EA, Lupien PJ, Brewer HB Jr, Raper SE, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995 Nov;1(11):1148-54.</citation>
    <PMID>7584986</PMID>
  </reference>
  <reference>
    <citation>Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH, Sanmiguel J, Morizono H, Batshaw ML, Wilson JM. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther. 2010 Jan;18(1):126-34. doi: 10.1038/mt.2009.245. Epub 2009 Nov 3.</citation>
    <PMID>19888196</PMID>
  </reference>
  <reference>
    <citation>Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004 Jun;78(12):6381-8.</citation>
    <PMID>15163731</PMID>
  </reference>
  <reference>
    <citation>Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009 Feb 1;199(3):381-90. doi: 10.1086/595830.</citation>
    <PMID>19133809</PMID>
  </reference>
  <reference>
    <citation>Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006 Mar;12(3):342-7. Epub 2006 Feb 12. Erratum in: Nat Med. 2006 May;12(5):592. Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added].</citation>
    <PMID>16474400</PMID>
  </reference>
  <reference>
    <citation>Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. doi: 10.1073/pnas.0904514106. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.</citation>
    <PMID>19706466</PMID>
  </reference>
  <reference>
    <citation>Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009 Sep 3;114(10):2077-86. doi: 10.1182/blood-2008-07-167510. Epub 2009 Jun 8.</citation>
    <PMID>19506302</PMID>
  </reference>
  <reference>
    <citation>Rader DJ, FitzGerald GA. State of the art: atherosclerosis in a limited edition. Nat Med. 1998 Aug;4(8):899-900.</citation>
    <PMID>9701240</PMID>
  </reference>
  <reference>
    <citation>Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.</citation>
    <PMID>22149959</PMID>
  </reference>
  <reference>
    <citation>Linton MF, Farese RV Jr, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest. 1993 Dec;92(6):3029-37.</citation>
    <PMID>8254057</PMID>
  </reference>
  <reference>
    <citation>Scanu AM, Khalil A, Neven L, Tidore M, Dawson G, Pfaffinger D, Jackson E, Carey KD, McGill HC, Fless GM. Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor. J Lipid Res. 1988 Dec;29(12):1671-81.</citation>
    <PMID>3244017</PMID>
  </reference>
  <reference>
    <citation>Hummel M, Li ZG, Pfaffinger D, Neven L, Scanu AM. Familial hypercholesterolemia in a rhesus monkey pedigree: molecular basis of low density lipoprotein receptor deficiency. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3122-6.</citation>
    <PMID>2326270</PMID>
  </reference>
  <reference>
    <citation>Chen SJ, Sanmiguel J, Lock M, McMenamin D, Draper C, Limberis MP, Kassim SH, Somanathan S, Bell P, Johnston JC, Rader DJ, Wilson JM. Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev. 2013 Dec;24(4):154-60. doi: 10.1089/humc.2013.082. Epub 2013 Nov 9.</citation>
    <PMID>24070336</PMID>
  </reference>
  <reference>
    <citation>Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F, Billheimer J, Wilson JM, Rader DJ. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther. 2013 Jan;24(1):19-26. doi: 10.1089/hum.2012.108. Epub 2012 Nov 14.</citation>
    <PMID>22985273</PMID>
  </reference>
  <reference>
    <citation>Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309.</citation>
    <PMID>25409372</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

